Literature DB >> 10411106

Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells.

F Imamura1, M Mukai, M Ayaki, K Takemura, T Horai, K Shinkai, H Nakamura, H Akedo.   

Abstract

Lysophosphatidic acid (LPA) triggers the invasion of a mesothelial cell monolayer by rat ascites hepatoma (MM1) cells. LPA also induces rapid morphological changes of MM1 cells, cell surface blebbing and pseudopodia formation. Pseudopodia formation is tightly correlated with cellular invasiveness. Clostridium Botulinum C3 exoenzyme and genistein abrogated the formation of blebs and pseudopodia together with the inhibition of invasion, indicating that GTPase Rho and certain tyrosine kinases are involved in both processes. MM1 cells expressing constitutively active Rho exhibited the invasion and the formation of blebs and pseudopodia in the absence of LPA. In contrast, MM1 cells expressing constitutively active Rac were not invasive in the absence of LPA, but were invasive in the presence of LPA. Their morphological response to LPA was almost the same as that of parental MM1 cells. Expression of dominant negative Rac suppressed the invasiveness to approximately 3% of that of parental MM1 cells, together with the inhibition of pseudopodia formation. Thus, Rho and Rac are cooperatively involved in both the invasion and the related morphological changes of MM1 cells. Rho activation is sufficient both for the induction of invasion and the morphological changes leading to the invasion, whereas Rac activation is necessary but not sufficient by itself. We propose that Rho activation is not mediated by Rac but the cooperation of both GTPases is essential to trigger the invasive behavior of MM1 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411106     DOI: 10.1023/a:1006598531238

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.

Authors:  A J Ridley; A Hall
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K.

Authors:  P J Keely; J K Westwick; I P Whitehead; C J Der; L V Parise
Journal:  Nature       Date:  1997-12-11       Impact factor: 49.962

3.  Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion.

Authors:  L M Shaw; I Rabinovitz; H H Wang; A Toker; A M Mercurio
Journal:  Cell       Date:  1997-12-26       Impact factor: 41.582

4.  Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia.

Authors:  H Nakahara; S C Mueller; M Nomizu; Y Yamada; Y Yeh; W T Chen
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

5.  A role for Rac in Tiam1-induced membrane ruffling and invasion.

Authors:  F Michiels; G G Habets; J C Stam; R A van der Kammen; J G Collard
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

6.  Lysophosphatidic acid: G-protein signalling and cellular responses.

Authors:  W H Moolenaar; O Kranenburg; F R Postma; G C Zondag
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

7.  Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D.

Authors:  F Imamura; T Horai; M Mukai; K Shinkai; M Sawada; H Akedo
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

8.  rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion.

Authors:  F Imamura; K Shinkai; M Mukai; K Yoshioka; R Komagome; T Iwasaki; H Akedo
Journal:  Int J Cancer       Date:  1996-03-01       Impact factor: 7.396

9.  Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells.

Authors:  A J Ridley; P M Comoglio; A Hall
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

10.  Serum requirement for in vitro invasion by tumor cells.

Authors:  F Imamura; T Horai; M Mukai; K Shinkai; H Akedo
Journal:  Jpn J Cancer Res       Date:  1991-05
View more
  7 in total

1.  Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy.

Authors:  M Opyrchal; C Allen; P Msaouel; I Iankov; E Galanis
Journal:  Cancer Gene Ther       Date:  2013-10-25       Impact factor: 5.987

Review 2.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

3.  Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis.

Authors:  Linda Sequeira; Cara W Dubyk; Tracy A Riesenberger; Carlton R Cooper; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2008-05-07       Impact factor: 5.150

4.  Lysophosphatidic acid induces cell migration through the selective activation of Akt1.

Authors:  Eun Kyoung Kim; Sung Ji Yun; Kee Hun Do; Min Sung Kim; Mong Cho; Dong-Soo Suh; Chi Dae Kim; Jae Ho Kim; Morris J Birnbaum; Sun Sik Bae
Journal:  Exp Mol Med       Date:  2008-08-31       Impact factor: 8.718

5.  RhoA is required for monocyte tail retraction during transendothelial migration.

Authors:  R A Worthylake; S Lemoine; J M Watson; K Burridge
Journal:  J Cell Biol       Date:  2001-07-09       Impact factor: 10.539

6.  Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase.

Authors:  F Imamura; M Mukai; M Ayaki; H Akedo
Journal:  Jpn J Cancer Res       Date:  2000-08

7.  Steering cell migration by alternating blebs and actin-rich protrusions.

Authors:  Alba Diz-Muñoz; Pawel Romanczuk; Weimiao Yu; Martin Bergert; Kenzo Ivanovitch; Guillaume Salbreux; Carl-Philipp Heisenberg; Ewa K Paluch
Journal:  BMC Biol       Date:  2016-09-02       Impact factor: 7.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.